ATE504310T1 - Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c - Google Patents

Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c

Info

Publication number
ATE504310T1
ATE504310T1 AT01910427T AT01910427T ATE504310T1 AT E504310 T1 ATE504310 T1 AT E504310T1 AT 01910427 T AT01910427 T AT 01910427T AT 01910427 T AT01910427 T AT 01910427T AT E504310 T1 ATE504310 T1 AT E504310T1
Authority
AT
Austria
Prior art keywords
disease
diseases
vascular
brain
activated protein
Prior art date
Application number
AT01910427T
Other languages
English (en)
Inventor
John Griffin
Berislav Zlokovic
Original Assignee
Scripps Research Inst
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Southern California filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE504310T1 publication Critical patent/ATE504310T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01910427T 2000-02-04 2001-02-05 Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c ATE504310T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18022700P 2000-02-04 2000-02-04
PCT/US2001/003758 WO2001056532A2 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Publications (1)

Publication Number Publication Date
ATE504310T1 true ATE504310T1 (de) 2011-04-15

Family

ID=22659693

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910427T ATE504310T1 (de) 2000-02-04 2001-02-05 Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c

Country Status (8)

Country Link
US (1) US7074402B2 (de)
EP (1) EP1255556B1 (de)
JP (1) JP2004508280A (de)
AT (1) ATE504310T1 (de)
AU (1) AU2001238034A1 (de)
CA (1) CA2398929C (de)
DE (1) DE60144366D1 (de)
WO (1) WO2001056532A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
JP4351041B2 (ja) 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
WO2004030619A2 (en) 2002-09-30 2004-04-15 Socratech L.L.C. Protein s protects the nervous system from injury
CA2508276C (en) * 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
EP1841442A4 (de) * 2005-01-07 2009-12-09 Northern Sydney And Central Co Behandlung von autoimmunkrankheiten und entzündlichen erkrankungen
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
EP2182978A4 (de) 2007-07-20 2012-03-21 Sanomune Inc Gewebe-kallikrein zur behandlung von erkrankungen im zusammenhang mit amyloid-protein
US8257700B2 (en) * 2008-02-05 2012-09-04 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions
CA2759490A1 (en) * 2009-04-22 2010-10-28 Sanomune Inc. Tissue kallikrein for the treatment of huntington's disease
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
CN104122396A (zh) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 维生素k依赖性蛋白s作为糖尿病标志物的应用
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
CN105806818B (zh) * 2016-04-01 2019-11-22 南京医科大学 检测血小板nmda受体活性的方法及其应用
EP3464322B1 (de) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Neuartige moleküle zur behandlung von entzündungen
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CA3176941A1 (en) * 2020-03-24 2021-09-30 Talengen International Limited Method and medicine for treating huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
ID23176A (id) * 1997-03-24 2000-03-23 Lilly Co Eli Metoda untuk mengobati gangguan pembuluh darah
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
US20020028199A1 (en) 2002-03-07
DE60144366D1 (de) 2011-05-19
CA2398929A1 (en) 2001-08-09
EP1255556A4 (de) 2003-07-02
WO2001056532A2 (en) 2001-08-09
EP1255556A2 (de) 2002-11-13
WO2001056532A3 (en) 2001-12-06
CA2398929C (en) 2011-05-31
JP2004508280A (ja) 2004-03-18
WO2001056532A9 (en) 2003-01-09
AU2001238034A1 (en) 2001-08-14
EP1255556B1 (de) 2011-04-06
US7074402B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
WO2004110389A3 (en) Sigma ligands for neuronal regeneration and functional recovery
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
KR960704839A (ko) β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production)
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DK1272208T3 (da) Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO2010036813A8 (en) Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2007053580A3 (en) Sigma ligands for neuronal regeneration and functional recovery
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
DE60133563D1 (de) Külen
WO2021222263A3 (en) Compositions and methods for treating inflammasome related diseases or conditions
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties